HALE DAVID F - 09 Dec 2021 Form 4 Insider Report for BIOCEPT INC

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 09 Dec 2021
Net transaction value: -$1,807
SEC form: 4
Accepted by SEC: 10 Dec 2021, 16:04:17 UTC
Prior SEC filing: 17 Aug 2021
Next SEC filing: 11 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ Michael Nall, Attorney-in-Fact

Key filing fact

HALE DAVID F filed Form 4 for BIOCEPT INC on 10 Dec 2021.

Key facts

This page summarizes HALE DAVID F's Form 4 filing for BIOCEPT INC.
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Dec 2021, 16:04.

Change

Previous filing in this sequence was filed on 17 Aug 2021.
Current net transaction value: -$1,807.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BIOC transaction

Common Stock

Sale

Transaction value: $1,474
Shares: -363
Change %: -10%
Price: $4.06
Shares after: 3,114
Date: 09 Dec 2021
Ownership: By LLC
Footnotes: F1

BIOC transaction

Common Stock

Sale

Transaction value: $44.79
Shares: -11
Change %: -9.8%
Price: $4.07
Shares after: 101
Date: 09 Dec 2021
Ownership: By trust
Footnotes: F1

BIOC transaction

Common Stock

Sale

Transaction value: $289
Shares: -71
Change %: -8.2%
Price: $4.07
Shares after: 796
Date: 09 Dec 2021
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The sales reported herein were made for tax planning purposes.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .